Skip to content

Toggle service links

You are here

  1. Home
  2. Research
  3. NEPC 2019

NEPC 2019

The Walton Hall building

One-day Symposium on

TREATMENT-EMERGENT NEUROENDOCRINE PROSTATE CANCER: CLINICAL RELEVANCE AND MOLECULAR PATHOGENESIS.

Venue: The Open University, Milton Keynes (MK7 6AA).

Date: 25/06/2019.

Scientific Committee: Prof. YZ Wang, University of British Columbia; Prof. Hardev Pandha, University of Surrey; Dr Francesco Crea, The Open University; Dr Rebecca Mather, The Open University. 

CPD Standards Office provider 60071

This meeting is accredited by the CPD Standards Office and is worth 5 hours CPD.

Watch videos of the conference presentations here;

Part 1 (session 1 speakers)

Part 2 (session 1 panel discussion)

Part 3 (session 2 speakers)

AGENDA

9:00-10:00 Registration (tea, coffee, biscuits)

Session 1 : CLINICAL ASPECTS OF TREATMENT-EMERGENT NEUROENDOCRINE PROSTATE CANCER

Session Chair: Dr Sushila Rigas, The Open University.

10-10.15 Welcome. 

Dr Martin Bootman, Director of Research LHCS, The Open University

10.15-11:00 The clinical progression of prostate cancer

Prof Hardev Pandha, Director of Surrey Cancer Centre.

11:00-11.30 Clinical characterization of treatment-emergent NEPC

Dr Francesco Crea, The Open University

11.30-12.30 Panel discussion: treatment-emergent NEPC: a new challenge for clinicians and researchers.

Dr Mark Eccleston, Volition; Mr Henry Andrews, Milton Keynes hospital (Urology); Prof Hardev Pandha, Surrey Cancer Centre; Dr Francesco Crea, The Open University 

12.30-2.00 Lunch and poster session 

Session 2 : MOLECULAR MECHANSISMS OF NEUROENDOCRINE TRANS-DIFFERENTIATION.

Session Chair: Dr Mario Colombo, Italian National Cancer Institute

2.00-2.45 The nature of neuroendocrine trans-differentiation: lessons learned from patient-derived xenografts.
Prof YZ Wang, BC Cancer Agency, Canada.

2.45-3.15 The long non-coding RNA landscape of neuroendocrine prostate cancer.  

Dr Rebecca Mather, The Open University.

3.15-3.45 The role of tumour microenvironment in neuroendocrine prostate cancer.
Dr Elena Jachetti, Italian National Cancer Institute.

4.00-4.30 Feedback opportunity

4.30-6:00

Networking(tea, coffee, biscuits)

News

Funding success: Understanding radio resistance in paediatric brain cancer

LHCS researchers Golding, Crea, Bacon and Stramek have assembled an international team to examine the genetic changes that occur in response to radiotherapy in the highly aggressive childhood brain cancer, known as DIPG.

1st July 2021
See all

Upcoming Events

No events

See All